Format

Send to

Choose Destination
Cleve Clin J Med. 2019 Jul;86(7):465-472. doi: 10.3949/ccjm.86a.18103.

Giant cell arteritis: An updated review of an old disease.

Author information

1
Internal Medicine Residency Program, Hennepin Healthcare, Minneapolis, MN, USA.
2
Rheumatology Fellowship Program, University of Minnesota, Minneapolis, MN, USA.
3
Rheumatology Division Director, Department of Medicine, Hennepin Healthcare, Minneapolis, MN, USA. rawad.nasr@hcmed.org.

Abstract

Giant cell arteritis is a common systemic vasculitis that affects the elderly and has a variable clinical presentation. Physicians should be aware of its different clinical phenotypes so that they can recognize it early and promptly initiate glucocorticoids, the mainstay of therapy. Clinicians should also be familiar with the toxicity of glucocorticoids and how to manage adverse effects. Tocilizumab, an interleukin 6 receptor inhibitor, is emerging as a glucocorticoid-sparing treatment, though its long-term safety and efficacy are still under study.

PMID:
31291180
DOI:
10.3949/ccjm.86a.18103
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center